Background Ongoing research seeks to identify blood-based biomarkers able to predict the onset and progression of Alzheimer’s disease (AD). A potential biomarker is the unfolded conformational variant of p53, previously observed in individuals in the prodromal and clinical AD stages. In this retrospective study, we compare diagnostic and prognostic performances of measures of the amyloid β load with those of a conformational variant of U-p53 in plasma samples from individuals participating in the Australian Imaging, Biomarkers and Lifestyle (AIBL) cohort.

中文翻译：

---

p53 的构象变异 (U-p53AZ) 作为基于血液的生物标志物，用于预测有症状的阿尔茨海默病的发作

背景正在进行的研究旨在确定能够预测阿尔茨海默病 (AD) 发病和进展的基于血液的生物标志物。一个潜在的生物标志物是 p53 的未折叠构象变异，以前在前驱期和临床 AD 阶段的个体中观察到。在这项回顾性研究中，我们比较了参与澳大利亚成像、生物标志物和生活方式 (AIBL) 队列的个体血浆样本中淀粉样蛋白 β 负载量与 U-p53 构象变异体的诊断和预后性能。